Adage Capital Partners
TRVI icon

Adage Capital Partners’s Trevi Therapeutics TRVI Stock Holding History

Adage Capital Partners’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-440,000
Closed -$2.77M – 951
2025
Q1 		$2.77M Sell
440,000
-2,060,000
-82% -$9.83M 0.01% 748
2024
Q4 		$10.3M Buy
+2,500,000
New +$8M 0.02% 596

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Adage Capital Partners's TRVI Position: Q2 2025 in Review

Adage Capital Partners sold out of Trevi Therapeutics (TRVI) in Q2 2025, closing a stake of 440,000 shares — an estimated $2.77M sold.

Adage Capital Partners first reported a position in TRVI in Q4 2024 and held it in 2 quarters. The position peaked at $10.3M in Q4 2024. 153 funds tracked by Wall St. Rank hold TRVI as of Q2 2025.

  • Adage Capital Partners reported no remaining Trevi Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Adage Capital Partners sold 440,000 Trevi Therapeutics shares in Q2 2025, an estimated $2.77M.
  • Adage Capital Partners first reported a position in Trevi Therapeutics in Q4 2024 and held it in 2 quarters.
  • Adage Capital Partners's Trevi Therapeutics position peaked at $10.3M in Q4 2024.
  • 153 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2025.

Based on Adage Capital Partners's 13F filing for Q2 2025, filed 14 Aug 2025.